title: Phentermine and topiramate for the management of obesity: a review.
abstract: Obesity is now a major public health concern worldwide with increasing prevalence and a growing list of comorbidities and complications. The morbidity, mortality and reduced productivity associated with obesity and its complications result in a major burden to health care costs. Obesity is a complex chronic medical syndrome often with multiple different etiologic factors in individual patients. The long term successful management of obesity remains particularly challenging and invariably requires a multifaceted approach including lifestyle and behavioral modification, increased physical activity, and adjunctive pharmacotherapy. Bariatric surgery remains a last resort though at present it has the best results for achieving sustained robust weight loss. Obesity pharmacotherapy has been very limited in its role for long term obesity management because of the past history of several failed agents as well as the fact that presently available agents are few, and generally utilized as monotherapy. The recent FDA approval of the fixed drug combination of phentermine and extended release topiramate (topiramate-ER) (trade name Qsymia™) marks the first FDA approved combination pharmacotherapeutic agent for obesity since the Phen-Fen combination of the 1990s. This review details the history and clinical trial basis for the use of both phentermine and topiramate in obesity therapeutics as well as the results of clinical trials of their combination for obesity treatment in humans. The initial clinical approval trials offer evidence that this fixed drug combination offers synergistic potential for effective, robust and sustained weight loss with mean weight loss of at least 10% of baseline achieved and sustained for up to 2 years in over 50% of subjects treated. It is anticipated that this agent will be the first in a new trend of multi-agent combination therapy for the chronic adjunctive management of obesity.
authors: Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
authors: Gina
authors: G
authors: Cosentino
authors: Ariane O
authors: AO
authors: Conrad
authors: Gabriel I
authors: GI
authors: Uwaifo
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005632:Fructose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D010645:Phentermine / Q000008:administration & dosage / Q000627:therapeutic use*; D000077236:Topiramate
chemical_list: D019440:Anti-Obesity Agents; D000077236:Topiramate; D005632:Fructose; D010645:Phentermine
keywords: anorexiants; cardiovascular risk factors; dysmetabolic syndrome; obesity; obesity complications; obesity pharmacotherapy
references: J Miss State Med Assoc. 2009 Dec;50(12):407-15
references: 20806811
references: Clin Pharmacol Ther. 1992 May;51(5):586-94
references: 1587072
references: J Nutr Health Aging. 2012 Jan;16(1):89-98
references: 22238007
references: Surg Clin North Am. 2012 Jun;92(3):559-82, viii
references: 22595709
references: J Clin Endocrinol Metab. 2009 Dec;94(12):4898-906
references: 19846734
references: Epilepsia. 1994 Mar-Apr;35(2):450-60
references: 8156972
references: Semin Thorac Cardiovasc Surg. 2011 Spring;23(1):24-9
references: 21807295
references: ACS Chem Neurosci. 2011 Sep 21;2(9):484-6
references: 22860172
references: J Diabetes Sci Technol. 2008 Sep;2(5):913-8
references: 19885278
references: Endocr Pract. 1997 Sep-Oct;3(5):269-75
references: 15251779
references: Expert Opin Drug Saf. 2012 May;11(3):459-71
references: 22439841
references: Obesity (Silver Spring). 2011 Dec;19(12):2351-60
references: 21527891
references: Nutr Rev. 2012 Jan;70(1):57-64
references: 22221216
references: Rev Med Suisse. 2011 Jan 12;7(277):57-60
references: 21309176
references: Metabolism. 1991 Mar;40(3):323-9
references: 2000046
references: Obes Facts. 2012;5(3):460-83
references: 22797374
references: Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801
references: 20707765
references: Annu Rev Public Health. 2012 Apr;33:409-23
references: 22224894
references: ACS Chem Neurosci. 2011 Apr 20;2(4):183-4
references: 22778866
references: Epilepsia. 2000;41(S1):3-9
references: 10768292
references: Lancet. 2011 Apr 16;377(9774):1341-52
references: 21481449
references: Clin Pharmacol Ther. 1992 May;51(5):595-601
references: 1587073
references: Lancet. 2011 Jul 9;378(9786):125-6; author reply 126-7
references: 21742167
references: Fundam Clin Pharmacol. 2010 Feb;24(1):37-42
references: 20002751
references: S D Med. 2012 Sep;65(9):356-7
references: 23066610
references: Obesity (Silver Spring). 2009 Sep;17(9):1730-5
references: 19300434
references: Int J Obes Relat Metab Disord. 1992 Apr;16(4):269-77
references: 1318281
references: Am J Ther. 2011 Jul;18(4):292-9
references: 20592662
references: Am J Hypertens. 2008 Oct;21(10):1124-8
references: 18772861
references: J Womens Health (Larchmt). 2005 Jun;14(5):382-6
references: 15989409
references: Int J Obes Relat Metab Disord. 2004 Nov;28(11):1399-410
references: 15486569
references: N Engl J Med. 2012 Oct 25;367(17):1577-9
references: 23050510
references: N Engl J Med. 2007 Nov 22;357(21):2109-22
references: 17984165
references: Drugs. 2012 Oct 22;72(15):2033-42
references: 23039320
references: Obes Res. 1997 Nov;5(6):578-86
references: 9449143
references: Obesity (Silver Spring). 2009 Jan;17(1):30-9
references: 18997675
references: Nat Clin Pract Gastroenterol Hepatol. 2005 Feb;2(2):89-95
references: 16265126
references: Curr Hypertens Rep. 2007 Jun;9(3):184-9
references: 17519122
references: Obes Res. 2004 Dec;12 Suppl:167S-73S
references: 15687413
references: Drugs. 2005;65(10):1391-418
references: 15977970
references: Curr Diab Rep. 2010 Apr;10(2):108-15
references: 20425569
references: Am J Cardiol. 2005 Jul 15;96(2):243-51
references: 16018851
references: Arch Intern Med. 2010 Jul 26;170(14):1191-1201
references: 20656674
references: J Obes. 2011;2011:179674
references: 21197148
references: Obes Res. 2003 Apr;11(4):556-62
references: 12690085
references: Curr Med Res Opin. 2012 Jun;28(6):969-77
references: 22494018
references: Am J Emerg Med. 2009 Oct;27(8):1010-3
references: 19857423
references: Evid Rep Technol Assess (Summ). 2004 Jul;(103):1-6
references: 15526396
references: Patient Prefer Adherence. 2012;6:555-63
references: 22927748
references: JAMA. 2005 Nov 23;294(20):2581-6
references: 16239637
references: Am J Clin Nutr. 2012 Feb;95(2):297-308
references: 22158731
references: Curr Opin Gastroenterol. 2002 Mar;18(2):213-20
references: 17033290
references: Br Med J. 1968 Feb 10;1(5588):352-4
references: 15508204
references: Obesity (Silver Spring). 2012 Feb;20(2):330-42
references: 22051941
references: Ann Intern Med. 2005 Sep 6;143(5):380-5
references: 16144896
references: Circulation. 2012 Oct 2;126(14):1770-9
references: 23027812
references: Ann Intern Med. 2005 Apr 5;142(7):532-46
references: 15809465
references: Am J Health Syst Pharm. 2007 Jun;64(12):1279-83
references: 17563050
references: CNS Neurosci Ther. 2008 Summer;14(2):120-42
references: 18482025
references: Pharm Res. 2011 Aug;28(8):1792-818
references: 21181547
references: Obes Res. 2003 Jun;11(6):722-33
references: 12805393
references: High Blood Press Cardiovasc Prev. 2012 Jun 1;19(2):55-7
references: 22867090
references: Prescrire Int. 2012 Sep;21(130):209
references: 23016252
references: JAAPA. 2011 Dec;24(12):58-63
references: 22315918
references: J Clin Endocrinol Metab. 2008 Nov;93(11 Suppl 1):S1-8
references: 18987267
references: Nat Rev Endocrinol. 2010 May;6(5):255-69
references: 20234354
references: Obes Res. 2005 Jan;13(1):118-22
references: 15761170
references: Bipolar Disord. 1999 Sep;1(1):42-53
references: 11256656
references: P T. 2011 May;36(5):255-62
references: 21785538
references: Headache. 2001 Nov-Dec;41(10):968-75
references: 11903524
references: Drugs Today (Barc). 2011 Dec;47(12):903-14
references: 22348915
references: J Clin Pharm Ther. 2012 Oct;37(5):525-35
references: 22462645
references: CMAJ. 2012 Jun 12;184(9):1039-44
references: 22586330
references: Lancet. 2011 Apr 16;377(9774):1295-7
references: 21497686
references: Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004096
references: 15674929
references: Recent Pat Endocr Metab Immune Drug Discov. 2012 May;6(2):117-28
references: 22435392